Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

Juhi Asad; Allyson F. Jacobson; Alison Estabrook; Sharon Rosenbaum Smith; Susan K. Boolbol; Sheldon M. Feldman; Michael P. Osborne; Kwadwo Boachie-Adjei; Wendy Twardzik; Paul I. Tartter

doi:10.1016/j.amjsurg.2008.06.021

Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

Juhi Asad, Allyson F. Jacobson, Alison Estabrook, Sharon Rosenbaum Smith, Susan K. Boolbol, Sheldon M. Feldman, Michael P. Osborne, Kwadwo Boachie-Adjei, Wendy Twardzik, Paul I. Tartter

Research output: Contribution to journal › Article › peer-review

116 Scopus citations

Abstract

Background: Oncotype DX is a 21-gene assay that calculates a risk of distant recurrence in women with estrogen-receptor-positive, lymph node-negative breast cancer. The purpose of this study was to determine whether the results of Oncotype DX influence the decision to administer chemotherapy. Methods: A retrospective study was performed on 85 consecutive patients with estrogen-receptor-positive, lymph node-negative breast cancer who had an Oncotype DX recurrence score (RS) obtained. Tumor size, tumor grade, and treatment were then compared within each risk category. Statistical analysis was performed using STATA software. Results: Tumors that were high grade and Her-2/neu positive more frequently had a high RS. Treatment was changed as a result of Oncotype DX in 44% of patients. Conclusions: Oncotype DX RS is significantly related to tumor grade and Her2/neu status. In this study, the treatment of 44% of patients was altered as a consequence of Oncotype DX RS.

Original language	English (US)
Pages (from-to)	527-529
Number of pages	3
Journal	American Journal of Surgery
Volume	196
Issue number	4
DOIs	https://doi.org/10.1016/j.amjsurg.2008.06.021
State	Published - Oct 2008
Externally published	Yes

Keywords

21-gene
Assay
Breast cancer
Management
Recurrence score

ASJC Scopus subject areas

Surgery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.amjsurg.2008.06.021

Cite this

@article{e1a672c232d440768689bf779f83fd7e,

title = "Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?",

abstract = "Background: Oncotype DX is a 21-gene assay that calculates a risk of distant recurrence in women with estrogen-receptor-positive, lymph node-negative breast cancer. The purpose of this study was to determine whether the results of Oncotype DX influence the decision to administer chemotherapy. Methods: A retrospective study was performed on 85 consecutive patients with estrogen-receptor-positive, lymph node-negative breast cancer who had an Oncotype DX recurrence score (RS) obtained. Tumor size, tumor grade, and treatment were then compared within each risk category. Statistical analysis was performed using STATA software. Results: Tumors that were high grade and Her-2/neu positive more frequently had a high RS. Treatment was changed as a result of Oncotype DX in 44% of patients. Conclusions: Oncotype DX RS is significantly related to tumor grade and Her2/neu status. In this study, the treatment of 44% of patients was altered as a consequence of Oncotype DX RS.",

keywords = "21-gene, Assay, Breast cancer, Management, Recurrence score",

author = "Juhi Asad and Jacobson, {Allyson F.} and Alison Estabrook and Smith, {Sharon Rosenbaum} and Boolbol, {Susan K.} and Feldman, {Sheldon M.} and Osborne, {Michael P.} and Kwadwo Boachie-Adjei and Wendy Twardzik and Tartter, {Paul I.}",

year = "2008",

month = oct,

doi = "10.1016/j.amjsurg.2008.06.021",

language = "English (US)",

volume = "196",

pages = "527--529",

journal = "American Journal of Surgery",

issn = "0002-9610",